Open Access Article
This Open Access Article is licensed under a Creative Commons Attribution-Non Commercial 3.0 Unported Licence

Catalyzed ring transformation of cyclic N-aryl-azadiperoxides with participation of α,ω-dithiols

Nataliya N. Makhmudiyarova*, Kamil R. Shangaraev, Irina R. Ishmukhametova, Askhat G. Ibragimov and Usein M. Dzhemilev
Institute of Petrochemistry and Catalysis, Russian Academy of Sciences, 141 Prospekt Oktyabrya, 450075 Ufa, Russian Federation. E-mail: natali-mnn@mail.ru

Received 17th November 2020 , Accepted 9th January 2021

First published on 21st January 2021


Abstract

Co(OAc)2-catalyzed ring transformation reaction of 10-aryl-7,8,12,13-tetraoxa-10-azaspiro[5.7]tridecanes with α,ω-dithiols (ethane-1,2-, propane-1,3-, butane-1,4-, pentane-1,5-, and hexane-1,6-dithiols, 3,6-dioxaoctane-1,8-dithiol) giving 3-aryl-1,5,3-dithiazacyclanes was studied.


Cyclic peroxides attract attention for their antimalarial,1 antibacterial,2 and antitumor3 activities. Among numerous cyclic peroxides, heteroatomic cyclic peroxides occupy a special place owing to their high biological activities.4 The methods of synthesis of heteroatom-containing cyclic peroxides are limited. Recently,5–10 nitrogen- and sulfur-containing cyclic di- and triperoxides with antitumor activity have been synthesized.5–9 The development of efficient methods for the preparation of new cyclic hetero-di(tri)peroxides5–10 promotes active investigation of their transformations. It was shown that the reduction of silatriperoxycycloalkanes with PPh3 affords siladiperoxycycloalkanes;11 the reaction of spiro{adamantane-[2,3′]-(pentaoxacane)} with o-phenylenediamine results in the synthesis of benzodioxazocine.5 The implemented conversion of pentaoxacane with o-phenylenediamine to benzodioxazocine5 suggests that cyclic N-containing peroxides can be involved in reactions with binucleophilic reagents, in particular α,ω-dithiols, to give new heterocycles. In contrast to the previously described methods of synthesis5–10 and transformation of the peroxide ring,5,11 this work for the first time discusses the method of catalytic conversion of tetraoxazaspirotridecane to dithiazacycloalkanes.

It was shown by preliminary experiments that the reaction of 10-phenyl-7,8,12,13-tetraoxa-10-azaspiro[5.7]tridecane 1 with ethane-1,2-dithiol 2 does not proceed without a catalyst. The reaction of azadiperoxide 1 with ethane-1,2-dithiol 2 catalyzed by Sm(NO3)3·6H2O, H2SO4 or BF3·Et2O in THF as a solvent affords 3-phenyl-1,5,3-dithiazepane 8 in 10–15% yield (Scheme 1, Table 1). It was found that the yield of 3-phenyl-1,5,3-dithiazepane12 is affected by the nature of the catalyst. When the reaction is carried out in a polar solvent (MeOH) in the presence of catalytic amounts of Sm(NO3)3·6H2O, H2SO4 or BF3·Et2O, the yield of the target product 8 increases to 30%. In the presence of the Co(OAc)2 catalyst, the yield of heterocycle 8 is 85%. When AlCl3 or CuCl catalysts are used, the yields of heterocycle 8 are 55% and 75%, respectively (Table 1). Under these conditions, cyclohexanone is formed and O2 is released (Scheme 1). All reactions were carried out at room temperature for 20 h.


image file: d0ra09758f-s1.tif
Scheme 1 Ring transformation reaction of 10-phenyl-7,8,12,13-tetraoxa-10-azaspiro[5.7]tridecane with α,ω-dithiols.
Table 1 Effect of the catalyst and solvent nature on the yield of 3-phenyl-1,5,3-dithiazacyclanes (∼20 °C, 20 h)
No. Compound [Cat] Solvent Yield, %
1 8 AlCl3 THF 45
2 8 AlCl3 MeOH 55
3 8 Co(OAc)2 THF 79
4 8 Co(OAc)2 MeOH 85
5 8 BF3·OEt2 THF 15
6 8 BF3·OEt2 MeOH 30
7 8 CuCl THF 68
8 8 CuCl MeOH 75
9 8 H2SO4 THF 13
10 8 H2SO4 MeOH 25
11 8 Sm(NO3)3·6H2O THF 10
12 8 Sm(NO3)3·6H2O MeOH 20
13 8 THF
14 8 MeOH
15 9 Co(OAc)2 MeOH 87
16 10 Co(OAc)2 MeOH 79
17 11 Co(OAc)2 MeOH 83
18 12 Co(OAc)2 MeOH 89
19 13 Co(OAc)2 MeOH 91


A probable pathway to the synthesis of 3-phenyl-1,5,3-dithiazepane 8 from 10-phenyl-7,8,12,13-tetraoxa-10-azaspiro[5.7]tridecane 1 includes13 coordination of the peroxide oxygen atom to the central atom of the catalyst, nucleophilic addition of ethane-1,2-dithiol to the resulting carbocation,14,15 and the subsequent ring closure giving heterocycle 8 (Scheme 2).


image file: d0ra09758f-s2.tif
Scheme 2 Probable synthesis mechanism for 3-phenyl-1,5,3-dithiazepane 8.

Under conditions including 5 mol% of Co(OAc)2, 20 °C, MeOH, and 20 h, 10-phenyl-7,8,12,13-tetraoxa-10-azaspiro[5.7]tridecane 1 was allowed to react with propane-1,3- 3, butane-1,4- 4, pentane-1,5- 5, and hexane-1,6-dithiols 6, which furnished the corresponding 3-phenyl-1,5,3-dithiaazacycloalkanes16 9–12 in 83–89% yields (Table 1). The ring transformation reaction of azadiperoxide 1 with 3,6-dioxa-1,8-octanedithiol 7 (monooxa derivative is shown in the scheme) under the conditions described above resulted in the synthesis of 6-phenyl-1,11-dioxa-4,8-dithia-6-azacyclotridecane16 12 in 91% yield (Scheme 1).

The discovered ring transformation reaction of azadiperoxide 1 with ethane-1,2-dithiol 2 was also carried out for 10-aryl-7,8,12,13-tetraoxa-10-azaspiro[5.7]tridecanes 14–24, which produced 3-aryl-1,5,3-dithiazepanes12 25–35 in 76–90% yields (Scheme 3).


image file: d0ra09758f-s3.tif
Scheme 3 Ring transformation reaction of 10-aryl-7,8,12,13-tetraoxa-10-azaspiro[5.7]tridecanes with ethane-1,2-dithiol.

In conclusion, we demonstrated that on treatment with α,ω-alkanedithiols and the Co(OAc)2 catalyst, azadiperoxides are converted to N-aryl-substituted 1,5,3-dithiazamacroheterocycles in high yields.

Conflicts of interest

The authors declare no conflict of interest.

Acknowledgements

The reported study was funded by RFBR according to the research project No. 20-33-90002/20.

Notes and references

  1. R. Slack, A. Jacobine and G. Posner, Med. Chem. Commun., 2012, 3, 281 RSC.
  2. V. Vil', I. Yaremenko, A. Ilovaisky and A. Terent'ev, Molecules, 2017, 22, 1881 CrossRef.
  3. D. Liu and J. Liu, Nat. Prod. Bioprospect., 2013, 3, 161 CrossRef CAS; M. P. Crespo-Ortiz and M. Q. Wei, Antitumor Activity of Artemisinin and Its Derivatives: From a Well-Known Antimalarial Agent to a Potential Anticancer Drug, J. Biomed. Biotechnol, 2012, 257597 Search PubMed.
  4. Y. Tu, Nat. Med., 2011, 17, 1217 CrossRef CAS.
  5. T. V. Tyumkina, N. N. Makhmudiyarova, G. M. Kiyamutdinova, E. S. Meshcheryakova, K. Sh. Bikmukhametov, M. F. Abdullin, L. M. Khalilov, A. G. Ibragimov and U. M. Dzhemilev, Tetrahedron, 2018, 74, 1749 CrossRef CAS.
  6. N. N. Makhmudiyarova, I. R. Ishmukhametova, L. U. Dzhemileva, T. V. Tyumkina, V. A. D'yakonov, A. G. Ibragimov and U. M. Dzhemilev, RSC Adv., 2019, 9, 18923 RSC.
  7. N. N. Makhmudiyarova, R. Sh. Rakhimov, T. V. Tyumkina, E. S. Meshcheryakova, A. G. Ibragimov and U. M. Dzhemilev, Russ. J. Org. Chem., 2019, 5, 620 CrossRef.
  8. N. N. Makhmudiyarova, K. R. Shangaraev, L. U. Dzhemileva, T. V. Tuymkina, E. S. Mescheryakova, V. A. D'yakonov, A. G. Ibragimov and U. M. Dzhemilev, RSC Adv., 2019, 9, 29949 RSC.
  9. N. N. Makhmudiyarova, I. R. Ishmukhametova, L. U. Dzhemileva, V. A. D'yakonov, A. G. Ibragimov and U. M. Dzhemilev, Molecules, 2020, 25, 1874 CrossRef CAS.
  10. N. N. Makhmudiyarova, I. R. Ishmukhametova, A. G. Ibragimov and U. M. Dhzemilev, Dokl. Chem., 2020, 492, 93 CrossRef CAS.
  11. N. N. Makhmudiyarova, I. R. Ishmukhametova and A. G. Ibragimov, Russ. J. Org. Chem., 2020, 10, 1495 Search PubMed.
  12. N. N. Murzakova, K. I. Prokof'ev, T. V. Tyumkina and A. G. Ibragimov, Russ. J. Org. Chem., 2012, 48, 588 CrossRef CAS.
  13. (a) S. Oda, J. Franke and M. Krishce, J. Chem. Sci., 2016, 7, 136 RSC; (b) S. Vojacek, K. Beese, Z. Alhalabi, S. Swyter, A. Bodtke, C. C. Schulzke, M. Jung, W. Sippl and A. Link, Arch. Pharm., 2017, 350, e1700097 CrossRef.
  14. U. J. Wellmar, Heterocyclic Chem, 1998, 35, 1531 CrossRef CAS.
  15. K. Krohn and S. Cludius-Brandt, Synthesis, 2010, 8, 1344 CrossRef.
  16. N. N. Makhmudiyarova, L. V. Mudarisova, E. S. Meshcheryakova, A. G. Ibragimov and U. M. Dzhemilev, Tetrahedron, 2015, 71, 259 CrossRef CAS.
  17. N. N. Makhmudiyarova, G. M. Khatmullina, R. Sh. Rakhimov, E. S. Meshcheryakova, A. G. Ibragimov and U. M. Dzhemilev, Tetrahedron, 2016, 72, 3277 CrossRef CAS.

Footnote

Electronic supplementary information (ESI) available. See DOI: 10.1039/d0ra09758f

This journal is © The Royal Society of Chemistry 2021
Click here to see how this site uses Cookies. View our privacy policy here.